Themis Medicare Ltd (THEMISMED) is currently trading at 90.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Themis Medicare is an integrated pharmaceutical company manufacturing finished formulations and synthetic Active Pharmaceutical Ingredients, operating manufacturing sites in Haridwar, Vapi and Artemis Biotech Hyderabad, exporting to over 44 countries and supplying hospital, critical care, and institutional customers while maintaining regulatory approvals including EU GMP for selected facilities. In Q1 FY27 consolidated revenue declined to ₹86.96 crore, down 10.9% year-on-year, while the company reported PBT of ₹38.6 crore and PAT of ₹24.6 crore; reported profits were materially supported by a one‑off profit on sale of shares (~₹92.95 crore), which masks underlying EBITDA weakness and operational headwinds in the API business. Balance sheet indicators show low leverage with Total Debt to Equity reported at 0.25 and market capitalisation near Rs.1,084 crore, but liquidity is constrained as cash and equivalents are modest (~₹4.5 crore) while trade receivables remain elevated, underscoring working capital intensity and the need for faster collections to support operations. Management’s strategic focus is on strengthening hospital and critical care businesses, recovering API and institutional segments, and commercialising in‑house APIs after the 2023 demerger; management targets growth through operational efficiency, targeted doctor outreach, and market expansion into RoW short-term and regulated markets like EU/USA within three to five years supported by R&D spend around 8% of revenue.

Over the past 52 weeks, Themis Medicare Ltd has traded between a low of ₹65.00 and a high of ₹141.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Themis Medicare Ltd has a market capitalization of approximately 832.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Themis Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.82 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 832.12 Cr, Themis Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Themis Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Themis Medicare Ltd is 20.82. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone PAT was ₹2.874 crore for the quarter ended June 30, 2026, compared with a loss of ₹1.537 crore in Q1 FY26.